ArticleInfection and drug resistance2022
Distribution of
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Phage-antibiotic combination: a possible approach to combatting multidrug-resistant Klebsiella pneumoniae.AMB Express · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation, characterization, and genomic analysis of novel bacteriophage AEV23 against multidrug-resistant Klebsiella pneumoniae isolated from Cystic Fibrosis patients.BMC microbiology · 2026Article
- One Health at Risk: Plasmid-Mediated Spread ofAntibiotics (Basel, Switzerland) · 2025Review
- Article
- Molecular characterization of superbugsHeliyon · 2024Article
- Characterizing the bacteriophage PKp-V1 as a potential treatment for ESBL-producing hypervirulent K1Veterinary world · 2024Article
- The Rapid Emergence of HypervirulentTropical medicine and infectious disease · 2024Review
- A Response to Article "Distribution of Mcr-1 Harboring Hypervirulent Klebsiella Pneumoniae in Clinical Specimens and Lytic Activity of Bacteriophage KpnM Against Isolates" [Letter].Infection and drug resistance · 2022Article
- A Response to Article "Distribution of Mcr-1 Harboring HypervirulentInfection and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The World Health Organization (WHO) has declared the multi-drug resistant (MDR) Methods: A total of 150 samples were collected from different clinical specimens through a convenient sampling technique. Isolation, identification, and antibiotic susceptibility testing (AST) of Results: Overall, a total of 41% of isolates of Conclusion: Significant distribution of mcr-1 harboring hypervirulent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.